Provath · Private markets, in the open

Search any private company and open it for the full read — what they raised, how they compare to peers, and who's behind it.

Sort by

Company	Sector	Latest stage	Raised	Modeled value est.	Rounds
Perkinelmer Inc · WALTHAM PerkinElmer \| Science with Purpose	Biotech	Growth/Late	$2.2B	$65.2B ($13.7B–$105.9B)	1
Sana Biotechnology, Inc. · SEATTLE Sana is creating engineered cells to repair and control genes in cells or replace missing or damaged cells to solve the underlying causes of disease.	Biotechnology	Growth/Late	$866.9M	$34.8B ($5.1B–$62.7B)	2
Catalent, Inc. · Somerset Catalent delivers end-to-end pharma solutions as a trusted CDMO, advancing drug development and manufacturing worldwide. Partner with us today!	Pharmaceuticals	Growth/Late	$650.0M	$23.6B ($4.3B–$42.5B)	1
Osteon Holdings, Inc. · FORT WORTH Services – Osteon Holdings	Pharma	Growth/Late	$617.0M	$22.4B ($4.0B–$40.4B)	1
Sage Therapeutics, Inc. · CAMBRIDGE	Pharmaceuticals	Growth/Late	$698.0M	$20.7B ($4.3B–$35.8B)	3
Neumora Therapeutics, Inc. · Watertown	Biotechnology	Growth/Late	$474.4M	$19.0B ($3.0B–$33.7B)	1
Allogene Therapeutics, Inc. · SOUTH SAN FRANCISCO	Biotechnology	Growth/Late	$411.8M	$17.5B ($2.6B–$31.5B)	1
Sarepta Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series D+	$430.5M	$16.5B ($1.8B–$36.1B)	2
Intarcia Therapeutics, Inc · Boston ABOUT US – Intarcia Life Sciences	Biotechnology	Growth/Late	$1.2B	$8.4B ($1.2B–$15.2B)	10
Recursion Pharmaceuticals, Inc. · SALT LAKE CITY Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us today!	Pharmaceuticals	Series D+	$478.3M	$8.3B ($1.2B–$17.8B)	8
Areteia Therapeutics, Inc. · CHAPEL HILL	Biotechnology	Series D+	$360.0M	$7.8B ($1.6B–$13.6B)	1
Bicycle Therapeutics Plc · CAMBRIDGE	Pharmaceuticals	Growth/Late	$555.5M	$7.3B ($3.6B–$9.4B)	1
Denali Therapeutics Inc. · SOUTH SAN FRANCISCO	Biotechnology	Growth/Late	$499.7M	$7.2B ($3.1B–$9.5B)	1
Verona Pharma plc · London	Pharmaceuticals	Series D+	$244.7M	$7.0B ($952.7M–$15.1B)	2
Par Health, Inc. · St. Louis Learn how Par Health’s legacy, values, and people shape a culture of excellence, integrity and unwavering dedication to those we serve.	Pharmaceuticals	Growth/Late	$763.0M	$6.8B ($5.0B–$7.8B)	1
Umoja Biopharma, Inc. · SEATTLE	Biotechnology	Series D+	$210.0M	$6.3B ($951.9M–$12.5B)	1
NiKang Therapeutics, Inc. · Wilmington	Biotechnology	Series D+	$200.0M	$6.2B ($906.7M–$12.2B)	1
Pyxis Oncology, Inc. · Cambridge	Pharma	Series D+	$194.5M	$5.0B ($821.1M–$10.1B)	2
Melinta Therapeutics, Inc. /New/ · NEW HAVEN	Pharmaceuticals	Series D+	$346.8M	$4.9B ($655.8M–$10.7B)	5
Gyroscope Therapeutics Ltd · STEVENAGE, HERTFORDSHIRE	Biotechnology	Series D+	$148.0M	$4.8B ($670.9M–$9.6B)	1
Beam Therapeutics Inc. · CAMBRIDGE	Pharmaceuticals	Series D+	$218.6M	$4.8B ($642.6M–$10.4B)	2
Semma Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series D+	$129.3M	$4.7B ($516.2M–$10.3B)	2
Century Therapeutics, Inc. · Philadelphia	Pharma	Series D+	$160.0M	$4.7B ($761.6M–$9.5B)	1
Dyne Therapeutics, Inc. · WALTHAM	Biotechnology	Series D+	$115.7M	$4.6B ($524.5M–$10.0B)	1
Chinook Therapeutics U.S., Inc. · SEATTLE	Biotechnology	Series D+	$180.0M	$4.5B ($521.3M–$9.8B)	2
Vividion Therapeutics, Inc. · SAN DIEGO	Biotechnology	Series D+	$240.7M	$4.5B ($612.0M–$9.2B)	4
iTeos Therapeutics, Inc. · CAMBRIDGE	Pharma	Series D+	$125.4M	$4.4B ($596.7M–$9.7B)	1
SpringWorks Therapeutics, Inc. · STAMFORD	Pharma	Series D+	$125.0M	$4.4B ($595.0M–$9.7B)	1
Tris Pharma, Inc. · MONMOUTH JUNCTION	Pharmaceuticals	Series D+	$125.0M	$4.4B ($595.0M–$9.7B)	1
Talaris Therapeutics, Inc. · LOUISVILLE	Biotechnology	Series D+	$115.0M	$4.4B ($521.3M–$9.4B)	1
Neon Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series D+	$106.0M	$4.4B ($480.5M–$9.6B)	1
JW (Cayman) Therapeutics Co. Ltd · Shanghai	Biotechnology	Series D+	$105.5M	$4.4B ($478.5M–$9.5B)	1
Neogene Therapeutics, Inc. · New York	Biotechnology	Series D+	$125.0M	$4.3B ($498.7M–$9.2B)	2
Unum Therapeutics Inc. · CAMBRIDGE	Biotechnology	Series D+	$220.5M	$4.3B ($473.3M–$9.3B)	4
Nurix Therapeutics, Inc. · SAN FRANCISCO	Pharma	Series D+	$144.7M	$4.2B ($572.4M–$9.3B)	4
Rubius Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series D+	$216.2M	$4.2B ($458.8M–$9.1B)	2
Pliant Therapeutics, Inc. · SOUTH SAN FRANCISCO	Biotechnology	Series D+	$162.6M	$4.1B ($455.4M–$9.1B)	2
Pear Therapeutics, Inc. · BOSTON	Pharma	Series D+	$254.8M	$4.1B ($628.3M–$8.5B)	4
Nutcracker Therapeutics, Inc. · EMERYVILLE	Biotechnology	Series D+	$172.5M	$4.1B ($655.1M–$7.8B)	4
Mirador Therapeutics, Inc. · San Diego	Pharma	Series D+	$413.0M	$4.0B ($1.6B–$5.8B)	2
Kyverna Therapeutics, Inc. · EMERYVILLE	Biotechnology	Series D+	$152.0M	$4.0B ($689.1M–$7.5B)	1
Janux Therapeutics, Inc. · La Jolla	Biotechnology	Series D+	$192.4M	$4.0B ($566.7M–$8.0B)	3
Kinnate Biopharma Inc. · SAN DIEGO	Biotechnology	Series C	$172.5M	$3.9B ($303.1M–$10.3B)	2
CinCor Pharma, Inc. · CINCINNATI	Biotechnology	Series D+	$142.9M	$3.9B ($647.7M–$7.5B)	1
Vor Biopharma Inc. · CAMBRIDGE	Pharma	Series D+	$110.1M	$3.9B ($524.2M–$8.5B)	1
Eikon Therapeutics, Inc. · HAYWARD	Biotechnology	Growth/Late	$1.1B	$3.8B ($2.2B–$4.6B)	4
Design Therapeutics, Inc. · Carlsbad	Pharmaceuticals	Series D+	$170.5M	$3.7B ($595.0M–$7.7B)	2
Stoke Therapeutics, Inc. · Bedford	Biotechnology	Series C	$90.8M	$3.7B ($278.4M–$9.7B)	2
4D Molecular Therapeutics Inc · EMERYVILLE	Biotechnology	Series C	$108.6M	$3.7B ($278.4M–$9.7B)	3
Ansun Biopharma, Inc. · SAN DIEGO	Pharma	Series C	$195.1M	$3.5B ($324.8M–$9.2B)	7
Sutro Biopharma Inc · SOUTH SAN FRANCISCO	Biotechnology	Series C	$85.4M	$3.5B ($264.1M–$9.2B)	1
Black Diamond Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series C	$146.3M	$3.5B ($262.9M–$9.2B)	4
Aimmune Therapeutics, Inc. · BRISBANE	Pharma	Series D+	$334.7M	$3.5B ($466.5M–$7.6B)	3
Finch Therapeutics Group, Inc. · SOMERVILLE	Biotechnology	Series C	$179.9M	$3.5B ($278.4M–$8.9B)	3
Saliogen Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series D+	$152.2M	$3.4B ($599.5M–$6.4B)	2
TScan Therapeutics, Inc. · Waltham	Biotechnology	Series C	$123.3M	$3.3B ($309.3M–$8.2B)	2
Inhibrx, Inc. · LA JOLLA Inhibrx \| Investors - Investors	Biotechnology	Growth/Late	$668.6M	$3.3B ($1.2B–$4.6B)	5
Edgewise Therapeutics, Inc. · Boulder	Biotechnology	Series C	$120.1M	$3.3B ($293.9M–$8.2B)	2
Genesis Therapeutics, Inc. · BURLINGAME	Biotechnology	Series D+	$297.4M	$3.3B ($1.0B–$5.1B)	3
Entrada Therapeutics, Inc. · BOSTON	Pharmaceuticals	Series D+	$150.9M	$3.3B ($553.3M–$6.6B)	3
Miragen Therapeutics, Inc. · Boulder	Biotechnology	Series C	$197.8M	$3.3B ($281.5M–$8.3B)	9
Larimar Therapeutics, Inc. · BALA CYNWYD	Biotechnology	Series C	$201.0M	$3.3B ($247.5M–$8.6B)	6
Silverback Therapeutics, Inc. · SEATTLE	Biotechnology	Series C	$139.3M	$3.2B ($262.9M–$8.2B)	4
Gossamer Bio, Inc. · SAN DIEGO Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).	Biotechnology	Series D+	$632.6M	$3.2B ($961.5M–$4.9B)	4
Cedilla Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series C	$82.6M	$3.1B ($255.5M–$8.1B)	1
Verve Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series C	$94.0M	$3.1B ($290.8M–$7.7B)	1
Tune Therapeutics, Inc. · SEATTLE	Biotechnology	Series D+	$182.4M	$3.1B ($826.9M–$5.0B)	1
Tmunity Therapeutics, Inc. · PHILADELPHIA	Biotechnology	Series C	$175.0M	$3.1B ($232.0M–$8.1B)	5
Xilio Therapeutics, Inc. · WALTHAM	Biotechnology	Series C	$145.2M	$3.0B ($293.9M–$7.3B)	2
Monte Rosa Therapeutics, Inc. · BOSTON	Biotechnology	Series C	$143.0M	$3.0B ($293.9M–$7.2B)	2
Oyster Point Pharma, Inc. · PRINCETON	Pharmaceuticals	Series C	$113.6M	$3.0B ($276.1M–$7.9B)	2
DTx Pharma, Inc. · SAN DIEGO	Pharmaceuticals	Series D+	$113.4M	$2.9B ($477.0M–$5.9B)	4
Scribe Therapeutics, Inc. · ALAMEDA	Pharma	Series D+	$100.0M	$2.9B ($476.0M–$5.8B)	1
Karyopharm Therapeutics Inc. · NEWTON	Pharmaceuticals	Series D+	$205.2M	$2.8B ($785.4M–$4.7B)	4
KSQ Therapeutics, Inc. · CAMBRIDGE	Pharmaceuticals	Series C	$80.6M	$2.8B ($261.8M–$7.5B)	1
TP Therapeutics, Inc. · SAN DIEGO	Pharmaceuticals	Series C	$126.4M	$2.8B ($259.8M–$7.4B)	3
Fulcrum Therapeutics, Inc. · CAMBRIDGE	Biotechnology	Series C	$183.2M	$2.8B ($211.9M–$7.4B)	4
Cidara Therapeutics, Inc. · SAN DIEGO	Biotechnology	Series D+	$349.1M	$2.8B ($1.1B–$4.0B)	7
Rain Therapeutics Inc. · Newark	Biotechnology	Series C	$92.0M	$2.8B ($224.6M–$7.2B)	3
Arcturus Therapeutics Ltd. · SAN DIEGO	Biotechnology	Series C	$67.8M	$2.8B ($209.7M–$7.3B)	1
Avalyn Pharma Inc. · SEATTLE	Biotechnology	Series D+	$244.0M	$2.7B ($857.6M–$4.1B)	4
Daisy Pharma Opioid Venture, LLC · SCOTTSDALE	Pharmaceuticals	Series C	$75.0M	$2.6B ($243.6M–$6.9B)	1
MEI Pharma, Inc. · SAN DIEGO	Pharmaceuticals	Series C	$76.1M	$2.6B ($243.6M–$6.9B)	2
Cyteir Therapeutics, Inc. · LEXINGTON	Biotechnology	Series C	$111.9M	$2.6B ($247.5M–$6.3B)	4
Aerovate Therapeutics, Inc. · BOSTON	Pharmaceuticals	Series C	$78.3M	$2.6B ($246.3M–$6.7B)	2
Celldex Therapeutics, Inc. · HAMPTON	Biotechnology	Series C	$64.5M	$2.6B ($193.3M–$6.7B)	2
Vera Therapeutics, Inc. · SOUTH SAN FRANCISCO	Biotechnology	Series C	$70.7M	$2.6B ($218.8M–$6.4B)	1
Landos Biopharma, Inc. · BLACKSBURG	Biotechnology	Series C	$60.3M	$2.5B ($186.4M–$6.5B)	1
Orna Therapeutics Holdings, LLC · CAMBRIDGE	Biotechnology	Series D+	$120.6M	$2.5B ($546.7M–$4.2B)	1
Kriya Therapeutics, Inc. · MORRISVILLE Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.	Biotechnology	Series D+	$870.3M	$2.5B ($1.5B–$3.0B)	4
Corvidia Therapeutics, Inc. · WALTHAM	Biotechnology	Series C	$60.0M	$2.5B ($185.6M–$6.5B)	1
Mereo Biopharma Group plc · LONDON	Pharmaceuticals	Series C	$70.0M	$2.5B ($227.4M–$6.5B)	1
Integrated Oncology Network Holdco, LLC · EVANSTON	Pharma	Series C	$69.9M	$2.5B ($227.0M–$6.5B)	1
Acrivon Therapeutics, Inc. · Watertown	Biotechnology	Series C	$115.5M	$2.4B ($309.3M–$5.3B)	2
Summit Therapeutics Inc. · Miami	Biotechnology	Series D+	$569.0M	$2.4B ($1.1B–$3.3B)	6
Autolus Therapeutics plc · London	Pharma	Series D+	$200.0M	$2.4B ($952.0M–$3.5B)	1
Spyre Therapeutics, Inc. · Waltham	Biotechnology	Series D+	$434.0M	$2.4B ($816.0M–$3.5B)	3
Carmot Therapeutics Inc. · BERKELEY	Biotechnology	Series D+	$349.8M	$2.4B ($680.0M–$3.7B)	6
Inozyme Pharma, Inc. · BOSTON	Pharmaceuticals	Series C	$116.2M	$2.4B ($218.9M–$6.2B)	2
Mineralys Therapeutics, Inc. · RADNOR	Pharmaceuticals	Series D+	$118.0M	$2.4B ($561.7M–$4.2B)	1

Companies